Investor FAQs

Show All
Where is Radius' stock traded?

Radius common stock is traded on the NASDAQ Global Market under the ticker symbol "RDUS."

What is your stock's CUSIP number?

750469 207

Where are Radius' headquarters located?

22 Boston Wharf Road
7th Floor
Boston, MA 02210

Can I buy Radius' stock directly from the company?

Radius does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.

Does Radius pay a dividend?

Radius does not currently pay a dividend.

Who is Radius' transfer agent?

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

 

Who do I contact about replacement of stock certificates?

To replace lost certificates, contact the transfer agent at:

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

 

I'm a shareholder; whom should I notify of a change in address?

To notify of a change in address, contact the transfer agent at:

Computershare
Investor Center Website
Shareholder Online Inquiries
Email

Telephone inquiries
1-877-373-6374 (US, Canada, Puerto Rico)
1-781-575-3100 (non-US)

Written requests
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

 

What is Radius' fiscal year?

Radius’ fiscal year is based on the calendar year.

First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.

What is the focus of Radius' business?

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.